Benhammane H, Mentha G, Tschanz E, El Mesbahi O, Dietrich P Y
Department of Medical Oncology, Hassan II University Hospital, Fez, Morocco.
Case Rep Oncol Med. 2012;2012:137291. doi: 10.1155/2012/137291. Epub 2012 Dec 19.
Background. Kaposi's sarcoma (KS) in transplant recipients is about 400 to 500 times rate in the general population. It is strongly associated to Human herpesvirus-8 (HHV-8) infection which has been found in 95% of KS lesions. The optimal approach to managing posttransplantation KS is to reduce or discontinue immunosuppressive therapy but this strategy carries a risk of the acute rejection of the graft. Recently, the use of an mTOR inhibitor has added new opportunities for KS treatment and prevention. Case Report. We report a case of 24 years-old Turkish woman with visceral HHV-8-associated Kaposi's sarcoma after orthotopic liver transplantation. Conclusion. Posttransplantation KS is considered an experimental model of virus induced tumor suggesting the usefulness of HHV-8 screening in transplant recipient and donor. Therapeutic approaches are complex and require a multidisciplinary team.
背景。移植受者中的卡波西肉瘤（KS）发病率约为普通人群的400至500倍。它与人类疱疹病毒8型（HHV-8）感染密切相关，在95%的KS病变中都发现了这种病毒。管理移植后KS的最佳方法是减少或停用免疫抑制治疗，但这种策略存在移植急性排斥反应的风险。最近，mTOR抑制剂的使用为KS的治疗和预防带来了新的机遇。病例报告。我们报告一例24岁土耳其女性在原位肝移植后发生内脏HHV-8相关卡波西肉瘤的病例。结论。移植后KS被认为是病毒诱导肿瘤的实验模型，提示对移植受者和供者进行HHV-8筛查的有用性。治疗方法复杂，需要多学科团队。
